Healthcare provider profile · identity verified

Sophia Smith, NP

Nurse Practitioner · WAUKESHA, WI · NPI 1154085215

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	206	28
Furosemide	Furosemide	152	28
Atorvastatin Calcium	Atorvastatin Calcium	144	25
Amlodipine Besylate	Amlodipine Besylate	143	28
Escitalopram Oxalate	Escitalopram Oxalate	134	15
Omeprazole	Omeprazole	118	20
Gabapentin	Gabapentin	111	18
Potassium Chloride	Potassium Chloride	105	16
Oxycodone Hcl	Oxycodone Hcl	83	59
Sertraline Hcl	Sertraline Hcl	81	19
Lisinopril	Lisinopril	75	14
Pantoprazole Sodium	Pantoprazole Sodium	74	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	69	38
Quetiapine Fumarate	Quetiapine Fumarate	69	12
Risperidone	Risperidone	66	suppressed
Metoprolol Succinate	Metoprolol Succinate	65	11
Tramadol Hcl	Tramadol Hcl	65	41
Trazodone Hcl	Trazodone Hcl	62	14
Buspirone Hcl	Buspirone Hcl	57	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	54	suppressed
Eliquis	Apixaban	51	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	48	suppressed
Lorazepam	Lorazepam	48	34
Famotidine	Famotidine	45	suppressed
Pregabalin	Pregabalin	45	20
Olanzapine	Olanzapine	43	suppressed
Memantine Hcl	Memantine Hcl	41	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	40	suppressed
Jardiance	Empagliflozin	37	suppressed
Clonazepam	Clonazepam	36	14
Donepezil Hcl	Donepezil Hcl	36	suppressed
Montelukast Sodium	Montelukast Sodium	34	suppressed
Simvastatin	Simvastatin	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Finasteride	Finasteride	32	suppressed
Mirtazapine	Mirtazapine	30	suppressed
Naproxen	Naproxen	30	suppressed
Ibuprofen	Ibuprofen	28	suppressed
Carvedilol	Carvedilol	26	suppressed
Fluticasone Propionate	Fluticasone Propionate	25	suppressed
Clonidine Hcl	Clonidine Hcl	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Latanoprost	Latanoprost	23	suppressed
Metformin Hcl Er	Metformin Hcl	23	suppressed
Xarelto	Rivaroxaban	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Losartan Potassium	Losartan Potassium	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Nystatin	Nystatin	19	12
Bupropion Hcl	Bupropion Hcl	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Amantadine	Amantadine Hcl	12	suppressed
Baclofen	Baclofen	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Glyburide-Metformin Hcl	Glyburide/Metformin Hcl	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Atenolol	Atenolol	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error